SOURCE: Revolutions Medical Corp.

Revolutions Medical Corp.

October 21, 2009 10:05 ET

RevMed Signs the First of Many Collaboration Agreements With Major Medical Universities

First Step Towards Application Validation of MRI Proprietary Software Technology

CHARLESTON, SC--(Marketwire - October 21, 2009) - Revolutions Medical Corporation ("RevMed" or the "Company") (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it has entered into a non-disclosure agreement ("NDA") with a major South Carolina university hospital (the "Hospital"). The agreement makes possible collaboration between RevMed and the Hospital on future applications of RevMed's proprietary MRI Technology.

"To put this in plain terms, with the exception of receiving FDA clearance for our RevVac safety syringe this is the single most important development in our Company's recent history," stated RevMed CEO Ron Wheet. "Our combined team is enthused about the possible uses in Alzheimer's, breast disease and stroke diagnoses. We believe that our color and 3D MRI technology could give vivid new insight into tissue status and structure, and perhaps lead to the earlier identification of these afflictions."

A veteran of numerous university collaborations in MRI technology, President Tom O'Brien added, "I know from first-hand experience just how important this step towards clinical credibility is. This collaboration will go a long way in validating our years of research and development. This relationship will be the first of many collaborations as we explore the full potential of our proprietary MRI technology."

To be added to the RevMed investor email list, please email with RMCP in the subject line.

About Revolutions Medical Corporation (

RevMed's products include the RevVac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information